机译:甲氨蝶呤,依托泊苷,地塞米松和Pegaspargase化疗的第2期研究,用于新诊断,复发或难治的外侧自然杀伤/ T细胞淋巴瘤,鼻型:中国西北部的多中心试验
Department of Hematology Xijing HospitalFourth Military Medical University710032 Xi'an Shaanxi;
Department of Hematology Xijing HospitalFourth Military Medical University710032 Xi'an Shaanxi;
Department of Hematology Xinan HospitalThird Military Medical UniversityChongqing China;
Department of HematologyGuiyang Medical UniversityGuiyang Guizhou Province China;
Department of HematologyXinjiang Autonomous Region HospitalWulumuqi Xinjiang Autonomous Region China;
Department of HematologyThe Affiliated Hospital of Kunming Medical UniversityKunming Yunnan;
Department of Hematology Xijing HospitalFourth Military Medical University710032 Xi'an Shaanxi;
Department of Hematology Xijing HospitalFourth Military Medical University710032 Xi'an Shaanxi;
Department of Hematology Xijing HospitalFourth Military Medical University710032 Xi'an Shaanxi;
Department of Hematology Xijing HospitalFourth Military Medical University710032 Xi'an Shaanxi;
Department of Hematology Xijing HospitalFourth Military Medical University710032 Xi'an Shaanxi;
Department of Hematology Xijing HospitalFourth Military Medical University710032 Xi'an Shaanxi;
Department of Hematology Xijing HospitalFourth Military Medical University710032 Xi'an Shaanxi;
Department of Hematology Xijing HospitalFourth Military Medical University710032 Xi'an Shaanxi;
Department of Hematology Xijing HospitalFourth Military Medical University710032 Xi'an Shaanxi;
Department of Hematology Xijing HospitalFourth Military Medical University710032 Xi'an Shaanxi;
chemotherapy; clinical trial; extranodal NK/T‐cell lymphoma; lymphoma; nasal type; non‐Hodgkin; refractory; relapse;
机译:甲氨蝶呤,依托泊苷,地塞米松和Pegaspargase化疗的第2期研究,用于新诊断,复发或难治的外侧自然杀伤/ T细胞淋巴瘤,鼻型:中国西北部的多中心试验
机译:吉西他滨,L-天冬酰胺酶,异环磷酰胺,地塞米松和依托泊苷化学疗法用于新诊断的IV期,复发性或难治性结外自然杀伤/ T细胞淋巴瘤,鼻型的研究
机译:回顾性研究表明,大剂量甲氨蝶呤,依托泊苷,地塞米松和培加斯加酶(MEDA)联合化疗可有效治疗晚期和复发/难治性结外自然杀伤/ T细胞淋巴瘤。
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:甲氨蝶呤依托泊苷地塞米松和培加aspargase化疗用于新诊断复发或难治性结外性自然杀伤/ T细胞淋巴瘤鼻型的2期研究:一项在西北地区的多中心试验
机译:用于新诊断,复发或难治的外杀鼠/ T细胞淋巴瘤,鼻腔类型的甲氨蝶呤,依托泊苷,地塞米松和PEGASPARGASE和PEGASPARGASE化学疗法的第2期研究:中国西北部的多中心试验